CW August 2005

category image Volume 14
Issue Number 8
August 2005
ISSN 10593802

Clinical Trials for a Promising Anti-Cancer Drug

Results from three phase II trials indicate that an investigational agent called temsirolimus, a derivative of rapamycin, has antitumor activity in varieties of deadly cancers.
Go to Previous Page
Go to Next Page

Source & Additional Reading

Journal of Clinical Oncology, August 10, 2005.

Purchase Downloadable Full-text PDF of Article: $10.00

Subscription is more cost effective than purchasing PDFs on-the-fly.  Click here for details.

Download Complete Issue CW August 2005

Purchase Downloadable Full-text PDF of Complete Issue: $20.00


Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us

Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA
phone: 518-456-0784; fax: 518-452-4955; email: info@adeninepress.com
copyright © Adeninepress, All rights reserved.




Re-initialize IP-based Login